PHASE II TRIAL OF EMD 121974 FOR RECURRENT GLIOBLASTOMA

该子项目是利用 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得主要资金， 因此可以在其他CRISP条目中表示。列出的机构是 中心，不一定是研究者的机构。 (from ClinicalTrials.gov请参阅 西仑吉肽（EMD 121974）可能通过阻断流向肿瘤的血流来阻止多形性胶质母细胞瘤的生长。手术前后给予西仑吉肽可能是治疗多形性胶质母细胞瘤的有效方法。 这项II期试验正在研究西仑吉肽在治疗复发性或进行性多形性胶质母细胞瘤手术患者中的作用。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. (from ClinicalTrials.gov) Cilengitide (EMD 121974) may stop the growth of glioblastoma multiforme by blocking blood flow to the tumor. Giving cilengitide before and after surgery may be an effective treatment for glioblastoma multiforme. This Phase II trial is studying how well cilengitide works in treating patients who are undergoing surgery for recurrent or progressive glioblastoma multiforme.